FisclearFisclear

Financial Comparison

Cipla Limited vs Divi's Laboratories Limited

Click a ticker to view the full analysis.

CIPLA.NS vs

In short

Divi's Laboratories Limited is the more profitable of the two, keeping 24.5% of revenue as net profit against 14.0% for Cipla Limited. Divi's Laboratories Limited trades at the higher trailing P/E (85.0× vs 31.9× for Cipla Limited), so investors pay more for each dollar of its earnings. Fisclear flags 0 medium- or high-severity risks for Cipla Limited and 1 for Divi's Laboratories Limited.

Based on filings for periods ending 31 Mar 2026 (CIPLA.NS) and 31 Mar 2026 (DIVISLAB.NS) · Updated

FisclearScore Comparison

CIPLA.NS51Fair
DIVISLAB.NS55Fair
Quality+6
89
83
Efficiency+15
47
62
Value
26
26
Cashflow+14
25
39
Regime
55
55
Peers
58
58

FisclearScore is a quantitative model. CIPLA.NS shown solid · DIVISLAB.NS shown dashed. Not financial advice.

MetricCIPLA.NSDIVISLAB.NS
Price₹1,310.50₹9,363.50
Market Cap₹1.06T₹2.49T
P/E (TTM)31.9x85.0x
P/B3.1x14.8x
Beta0.090.23
Div Yield0.99%0.32%
Revenue (TTM)₹277.1B₹104.8B
Net Income₹38.8B₹25.7B
Gross Margin62.3%59.1%
Risk Flags—1 flag
Full CIPLA.NS Report →Full DIVISLAB.NS Report →

Related comparisons

CIPLA.NS vs Sun PharmaceuticalDIVISLAB.NS vs Sun PharmaceuticalCIPLA.NS vs Dr. Reddy's LaboratoriesDIVISLAB.NS vs Dr. Reddy's LaboratoriesAPOLLOHOSP.NS vs CIPLA.NSCIPLA.NS vs TORNTPHARM.NS

Data sourced from SEC EDGAR, Yahoo Finance, and official exchange filings. For informational purposes only. Not financial advice.